MDMA is a non-selective monoamine releasing stimulant with potent serotonergic effects - a pharmacological effect not typically associated with drugs of misuse or efficacious reinforcers. Nonetheless, MDMA is misused by humans and self-administered by laboratory animals. We have previously shown that repeated exposure to MDMA sensitized both the locomotor activating and reinforcing effects of MDMA in rats. Because repeated MDMA exposure often results in decreased markers of serotonin neurotransmission, it is possible that this might underlie the sensitizing effects of MDMA. This was examined in the current study. Male Sprague-Dawley rats were stereotaxically implanted with guide cannula in the medial striatum. They were then pre-treated with saline (n =  11) or MDMA (10 mg/kg, i.p.; n =  10), once daily for five days. Two-days later, all rats received ascending doses of MDMA (0.0, 5.0, 10.0, mg/kg, i.p.) administered at 2 hr intervals, during which locomotor activity was measured and microdialysis samples were collected. Microdialysates were analyzed using liquid chromatography-mass spectrometry and the concentrations of serotonin and MDMA were quantified. Acute MDMA administration produced dose-dependent increases in locomotor activity, which was significantly enhanced by MDMA pre-treatment. Acute MDMA also produced dose-dependent increases in medial-striatal serotonin and MDMA, but this was not impacted by MDMA pre-treatment. These results suggest that the sensitizing effects of MDMA are not due to changes in MDMA-produced synaptic overflow of serotonin in the medial striatum or the absorption/elimination of systemically administered MDMA. More likely candidates are alterations in serotonin receptor mechanisms and/or dopamine neurotransmission following repeated exposure.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbr.2022.113936DOI Listing

Publication Analysis

Top Keywords

mdma
18
effects mdma
16
serotonin mdma
12
sensitizing effects
12
repeated exposure
8
medial striatum
8
locomotor activity
8
acute mdma
8
produced dose-dependent
8
dose-dependent increases
8

Similar Publications

Urine drug screening is carried out on numerous automated analysis platforms using enzyme-linked immunosorbent assays. While these methods are rapid, they often lack specificity. We report the case of a 5-year-old child treated for Dravet disease and hospitalized for clonic seizures.

View Article and Find Full Text PDF

Background: Ketamine's potential for treating depression has drawn increased clinical interest in recent years. However, despite growing therapeutic use, recreational use among individuals with depression remain underexplored.

Methods: We analyzed data from the 2015-2022 National Survey on Drug Use and Health for adults in the US.

View Article and Find Full Text PDF

Interest and limits of using pharmacogenetics in MDMA-related fatalities: A case report.

Forensic Sci Int Genet

December 2024

Service de Pharmacologie-Toxicologie et Pharmacovigilance, Centre Hospitalo-Universitaire d'Angers, Angers, France.

Interpreting postmortem concentrations of 3,4-Methylenedioxymethamphetamine (MDMA) remains challenging due to the wide range of reported results and the potential idiosyncratic nature of MDMA toxicity. Consequently, forensic pathologists often rely on a body of evidence to establish conclusions regarding the cause and the manner of death in death involving MDMA. Given these issues, implementing pharmacogenetics' (PGx)' testing may be beneficial.

View Article and Find Full Text PDF

Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration.

Am J Psychiatry

January 2025

Directorate of Behavioral Health, Walter Reed National Military Medical Center, Bethesda, Md. (Wolfgang); Department of Psychiatry, Uniformed Services University, Bethesda, Md. (Wolfgang, Benedek); Department of Psychiatry, Yale University School of Medicine, New Haven, Conn. (Wolfgang, Wiechers); Department of Veterans Affairs, Office of Research and Development, Washington, D.C. (McClair, Smyth, Tenhula); Department of Veterans Affairs, Executive Division, National Center for PTSD, White River Junction, Vt. (Schnurr, Holtzheimer); Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, N.H. (Schnurr, Holtzheimer); Department of Psychiatry and Behavioral Sciences, University of California, San Francisco. (Woolley, Wiechers); San Francisco Veterans Affairs Medical Center, San Francisco. (Woolley); Department of Psychiatry, Oregon Health and Science University, Portland, Ore. (Stauffer); Department of Mental Health; VA Portland Health Care System, Portland, Ore. (Stauffer); Substance Abuse and Mental Health Services Administration, Rockville, Md. (Wolf); Department of Health and Human Services, Office of the Assistant Secretary for Health, Washington, D.C. (States); Department of Psychiatry, Harvard Medical School, Boston (Bradley); VA Boston Healthcare System, Boston (Bradley); Department of Veterans Affairs, Pharmacy Benefits Management Service, Washington, D.C. (Fuller); Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio (Fuller); Department of Veterans Affairs, Northeast Program Evaluation Center, Office of Mental Health, Washington, D.C. (Hermes); Veterans Health Administration Office of Mental Health, Washington, D.C. (Wiechers).

View Article and Find Full Text PDF

MDMA and MDMA-Assisted Therapy.

Am J Psychiatry

January 2025

Directorate of Behavioral Health, Walter Reed National Military Medical Center, Bethesda, MD (Wolfgang); Departments of Psychiatry (Wolfgang) and Medical and Clinical Psychology (Gray), Uniformed Services University, Bethesda, MD; Departments of Psychiatry (Wolfgang, Krystal), Neuroscience (Krystal), and Psychology (Krystal), Yale University School of Medicine, New Haven, CT; Center for Psychedelic Research and Therapy, Department of Psychiatry and Behavioral Sciences, The University of Texas at Austin Dell Medical School (Fonzo, Nemeroff); Department of Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine, UCLA (Grzenda); Department of Psychiatry & Behavioral Sciences, University of Minnesota, Minneapolis (Widge); Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham (Kraguljac); Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (McDonald); Department of Psychiatry and Behavioral Sciences, Stanford University and Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (Rodriguez).

Article Synopsis
  • MDMA, also known as Ecstasy or Molly, has been used since the 1970s for both recreational and therapeutic purposes, with the FDA recognizing its potential for treating PTSD as a Breakthrough Therapy in 2017.
  • The effects of MDMA in therapeutic settings are distinct, promoting trust and self-compassion while allowing cognitive clarity, which differentiates it from other psychedelics.
  • Preliminary evidence indicates that MDMA-Assisted Therapy is effective, with 67%-71% of PTSD patients no longer meeting diagnostic criteria after treatment, significantly more than those receiving placebo therapy.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!